-
1 Comment
Zhongzhu Healthcare Holding Co.,Ltd is currently in a long term uptrend where the price is trading 23.3% above its 200 day moving average.
From a valuation standpoint, the stock is 57.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.
Zhongzhu Healthcare Holding Co.,Ltd's total revenue rose by 19.8% to $178M since the same quarter in the previous year.
Its net income has increased by 63.0% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.5% to $96M since the same quarter in the previous year.
Based on the above factors, Zhongzhu Healthcare Holding Co.,Ltd gets an overall score of 4/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE0000017X8 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.2 |
|---|---|
| PE Ratio | None |
| Target Price | 12.5 |
| Market Cap | 3B |
| Dividend Yield | None |
Zhongzhu Healthcare Holding Co.,Ltd engages in the research, development, production, and sales of pharmaceuticals drugs in China. It offers ophthalmology drugs, including pearl eye drops, sodium cromoglycate eye drops solution, acyclovir eye drops, hydroxybenzazole hydrochloride eye drops, acyclovir dispersible tablets, gatifloxacin tablets, etc. It is also involved in production and sales of products, including hepatest ultrasonic liver cirrhosis detector, infusion heater, Luna God full-body gamma knife, etc. In addition, the company engages in residential real estate development, capital market services, technology promotion and application service, medical services and devices, special equipment manufacturing, software and information technology service, hospital investment management, leasing and business services. The company researches and develops drugs, such as Genistein capsule which has completed the phase 2 clinical research for the prevention and treatment of women's menopausal syndrome, osteoporosis, and anti-tumor effect; Leonurine sulfate tablets, which has completed phase 1b clinical study for the prevention and treatment of cardiovascular and cerebrovascular diseases and strokes; and motherwort. The company was formerly known as Zhongzhu Holding Co., Ltd. and changed its name to Zhongzhu Healthcare Holding Co., Ltd in June 2016. The company was founded in 1970 and is headquartered in Zhuhai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600568.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
